Table 12.
General information and characteristics of the candidiasis described for Candida pulcherrima.
| Invasive/Noninvasive Candidiasis (n Human Cases/Strains/Isolates) |
Identification Methods |
Imaging Test |
Antifungal Susceptibility |
Antifungal Resistance |
Antifungal Treatment |
Other treatments (e.g., Probiotics, Natural Compounds, Antivirals) |
Outcome (n) |
Reference(s) |
|---|---|---|---|---|---|---|---|---|
| (invasive) C.pulcherrima (n = 1) |
Blood culture | Microscopy and ITS sequencing | Amphotericin B lipid complex | NR | Amphotericin B lipid complex | NA | Alive | [195] |
| (invasive) C.pulcherimma (n = 1) |
Blood culture | MALDI-TOF MS | Fluconazole | NR | Fluconazole | NA | Alive | [197] |
| (invasive) C. pulcherimma (n = 1) |
Blood culture | Microscopy and ITS sequencing | Liposomal amphotericin B, fluconazole, voriconazole, posoconazole, micafungin, anidulafungin |
NR | Liposomal amphotericin B and micafungin | NA | Alive | [196] |
| (invasive) C. pulcherimma (n = 1) |
Blood cultures | Microscopy and MALDI-TOF MS | Amphotericin B, azoles, echinocandins |
NR | Amphotericin B, voriconazole, echinocandins |
NA | Alive | [196] |
MIC: Minimal inhibitory concentrations; NR: not reported; NA: nonapplicable: PCR: polymerase chain reaction; MALDI-TOF MS: matrix-assisted laser desorption ionization mass spectroscopy; ITS: internal transcribed spacer.